Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.

Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD).

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements related to the further development and potential safety, efficacy, commercialization and other characteristics of tanespimycin and Kosan's development plans with respect to tanespimycin, including but not limited to Kosan's plans for the TIME registration program. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of tanespimycin, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Revlimid(R) (lenalidomide) is a registered trademark of Celgene Corporation

Cremophor(R) is a registered trademark of BASF Corporation


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  ADM Tronics Unlimited, Inc. (OTCQB: ... to its corporate Advisory Board for business development. ... the Harvard Medical School and Visiting Professor at ... his Masters degree in Electronics Engineering and his ... of Bologna. After spending a year as a ...
(Date:9/18/2014)... 18, 2014  ePharmaSolutions, the leading provider ... the Disruptive Innovator of the Year at ... platform. This solution includes an integrated clinical ... (eTMF), a remote monitoring application, eSource and ... screening and matching technology. The ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... United Arab Emirates, Sept. 22 NewBridge Pharmaceuticals announced ... agreement with Orexo AB (STO: ORX) that grants NewBridge ... treatment of breakthrough cancer pain, in the Middle East ... and sell the product in these territories.  The agreement ...
... Decision Resources, one of the world,s leading research and ... to generic erosion of key agents, the colorectal cancer drug ... from more than $6.4 billion in 2009 to just under ... Italy, Spain, United Kingdom and Japan. The Pharmacor ...
Cached Medicine Technology:NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 2NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 3NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa 4Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019 2Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019 3
(Date:9/18/2014)... September 18, 2014 According to a new ... Services Market - Global Industry Analysis, Size, Share, Growth, Trends ... services market was valued at USD 77607.7 million in 2013 ... from 2014 to 2020, to reach an estimated value of ... and services market is growing at a rapid pace due ...
(Date:9/18/2014)... September 18, 2014 The new ... boon to contractors and homeowners alike as it ... overtakes the home, causes potential health issues, and ... nationwide, the BuildClean system allows contractors to virtually ... and other standard remodeling tasks. , BuildClean removes ...
(Date:9/18/2014)... T-System Inc. today announced Holyoke Medical ... — EV™ for physicians — improving ... best-of-breed solutions, Holyoke chose T-System’s solution because not ... and reimbursement, but also its ability to integrate ... used to capture emergency department, (ED) nurse documentation. ...
(Date:9/18/2014)... the popular online supplier of funny figurines, has added a ... line. Moreover, all the company’s products are now offered with ... special offer before September 29, 2014. Customers who place bulk ... bobblehead doll ). , “We are pleased to ... make our interesting items available to all the global customers. ...
(Date:9/18/2014)... How much is a serving? , Most ... to the obesity epidemic in the United States. ... to manage portion size during the next “Healthy Eating ... House, 755 Ohltown Road, Austintown. , Registered dietician and ... and answer questions from 12:30 to 2 p.m. Oct. ...
Breaking Medicine News(10 mins):Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2Health News:Discounted Custom Bobbleheads Online For Sale At WowBobble.com 2Health News:HMHP Workshop Addresses Portion Control 2
... N.Y. study finds that weather warmer than 75 degrees poses ... research suggests that cocaine overdose deaths in New York City ... average weekly temperature goes past 75 degrees Fahrenheit. , ... Addiction , are based on death statistics in the city ...
... Researchers say defibrillators can be turned off on admission, ... care for people who are dying often forget to ... research has found. , Only 20 percent of more ... that they had a question on their admitting form ...
... , ... ... ... ...
... ... ... , ... , , , ...
... new study, led by researchers at the Herbert Irving ... demonstrates that acupuncture may be an effective therapy for ... are being treated with commonly used hormonal therapies. Results ... . Joint pain and stiffness are common side ...
... it possible to build supercomputers that can replicate the ... to an implantable chip for interfacing with neurons and ... nanoscience and neuroscience are now advancing each other in ... what this means was the topic of an hour-long ...
Cached Medicine News:Health News:Hearts of Hospice Patients Being Needlessly Shocked 2Health News:Hearts of Hospice Patients Being Needlessly Shocked 3Health News:American Dental Association President Testifies Before IOM Committee on Access to Oral Health Care 2Health News:American Dental Association President Testifies Before IOM Committee on Access to Oral Health Care 3Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 2Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 3Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 4Health News:Healthcare Trust of America, Inc. Acquires an 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia for $19,550,000 5Health News:Acupuncture may relieve joint pain caused by some breast cancer treatments 2
Inquire...
Inquire...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
Medicine Products: